Blogs

The AccelTRA^® components program was developed to help generics manufacturers meet increasing quality standards, facilitate fast response to market variability and standardize around a next generation formulation for simplicity. Initially introduced with stopper configurations in 13mm and 20mm serum and lyo formats, the benefits under the program support the needs of the generics market to minimize the risk for quality by having an industry leading Extractables package, in addition to an optimized supply chain, ensuring 6-week lead times on commercial orders.

Recently, the generics pharmaceutical industry in the United States has seen the average time to market decrease significantly as approvals have steadily increased thanks to the introduction of the Generic Drug User Fee Amendments (GDUFA) in October 2012. The reduction in time has led pharmaceutical companies to seek out high-quality elastomer products that provide the regulatory simplicity necessary to bring their products to market quickly, helping to increase a company’s competitiveness and their drug product’s overall sales. The AccelTRA™ elastomer program is built on these features: Quality, Speed, Simplicity.

West is pleased to announce that the AccelTRA™ component program has been recognized with a 2018 India Packaging Award in the category of “Packaging Design in Injectables.”  The award was announced during a ceremony at the 2018 InnoPack Pharma Confex in Mumbai, India on May 24, 2018.

When it comes to accelerating speed to market, there are several significant challenges generic manufacturers face. In a recent webinar hosted by FiercePharma, West experts from marketing, quality and regulatory affairs, as well as technical customer support presented on trends in the global injectable market and offered several key market insights that are driving primary packaging containment for generic manufacturers. The seminar highlighted West’s new AccelTRA™ component platform.